
S10 Ep40: FDA Approval Insights: Imetelstat in Lower-Risk MDS and Transfusion-Dependent Anemia
OncLive® On Air
00:00
FDA Approval Insights on Telomerase Inhibition in MDS
This chapter explores the FDA's approval of a telomerase inhibitor for lower-risk myelodysplastic syndromes, emphasizing results from the eMERGE trial. Notable findings include a 40% rate of transfusion independence and significant hemoglobin improvements among patients, demonstrating sustained efficacy.
Transcript
Play full episode